UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Repositioning HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors for the treatment of SARS-CoV-2 infection and COVID-19

European journal of clinical pharmacology, 2021-09, Vol.77 (9), p.1297-1307

von Hentig, Nils

2021

Volltextzugriff (PDF)

Sequential Population Pharmacokinetic Modeling of Lopinavir and Ritonavir in Healthy Volunteers and Assessment of Different Dosing Strategies

Antimicrobial Agents and Chemotherapy, 2011-06, Vol.55 (6), p.2775-2782

2011

Volltextzugriff (PDF)

Cross-sectional Assessment of the Consequences of a GTP Cyclohydrolase 1 Haplotype for Specialized Tertiary Outpatient Pain Care

The Clinical journal of pain, 2009-11, Vol.25 (9), p.781-785

2009

Volltextzugriff (PDF)

Cytochrome P450 3A Inhibition by Atazanavir and Ritonavir, but Not Demography or Drug Formulation, Influences Saquinavir Population Pharmacokinetics in Human Immunodeficiency Virus Type 1-Infected Adults

Antimicrobial Agents and Chemotherapy, 2009-08, Vol.53 (8), p.3524-3527

2009

Volltextzugriff (PDF)

Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapy

HIV/AIDS (Auckland), 2016-01, Vol.8 (Issue 1), p.1-16

von Hentig, Nils

2016

Volltextzugriff (PDF)

Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution

Pharmacogenetics and genomics, 2009-06, Vol.19 (6), p.407-414

2009

Volltextzugriff (PDF)

Determination of lopinavir/ritonavir concentrations in four different oral solutions for the application of antiretroviral therapy in very young, HIV-1-infected children

Southern African journal of HIV medicine, 2021, Vol.22 (1), p.1222-1222

2021

Volltextzugriff (PDF)

Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers

Pharmacogenetics and genomics, 2009-06, Vol.19 (6), p.429-436

2009

Volltextzugriff (PDF)

Messung von Plasmakonzentrationen antiretroviraler Arzneimittel in der HIV-Therapie

Deutsche medizinische Wochenschrift, 2008-02, Vol.133 (5), p.191-195

von Hentig, N

2008

Volltextzugriff (PDF)

Evaluation of Platelet Activation by HIV Protease Inhibitors – The HIV-PLA II Study

HIV/AIDS (Auckland), 2021-01, Vol.13, p.789-800

2021

Volltextzugriff (PDF)

Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults

European journal of clinical pharmacology, 2007-10, Vol.63 (10), p.935-940

2007

Volltextzugriff (PDF)

The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors

Journal of antimicrobial chemotherapy, 2008-09, Vol.62 (3), p.579-582

2008

Volltextzugriff (PDF)

Significant effects of tipranavir on platelet aggregation and thromboxane B[sub]2 formation in vitro and in vivo

Journal of antimicrobial chemotherapy, 2008-02, Vol.61 (2), p.394

2008

Volltextzugriff (PDF)

Platelet–leucocyte adhesion markers before and after the initiation of antiretroviral therapy with HIV protease inhibitors

Journal of antimicrobial chemotherapy, 2008-11, Vol.62 (5), p.1118-1121

2008

Volltextzugriff (PDF)

Pharmacokinetics of Saquinavir, Atazanavir, and Ritonavir in a Twice-Daily Boosted Double-Protease Inhibitor Regimen

Antimicrobial Agents and Chemotherapy, 2007-04, Vol.51 (4), p.1431-1439

2007

Volltextzugriff (PDF)

Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time

Thrombosis and haemostasis, 2004-06, Vol.91 (6), p.1137-1145

2004

Volltextzugriff (PDF)

Association of Saquinavir Plasma Concentrations with Side Effects but Not with Antiretroviral Outcome in Patients Infected with Protease Inhibitor-Susceptible Human Immunodeficiency Virus Type 1

Antimicrobial Agents and Chemotherapy, 2007-09, Vol.51 (9), p.3264-3272

2007

Volltextzugriff (PDF)

Decrease of Atazanavir and Lopinavir Plasma Concentrations in a Boosted Double Human Immunodeficiency Virus Protease Inhibitor Salvage Regimen

Antimicrobial Agents and Chemotherapy, 2008-06, Vol.52 (6), p.2273-2275

2008

Volltextzugriff (PDF)

New Antiretrovirals on the Block: Pharmacological news from Croi 2017

Journal of antivirals & antiretrovirals, 2017, Vol.9 (1)

Hentig, Nils von

2017

Volltextzugriff (PDF)

New Antiretrovirals on the Block: Pharmacological news from Croi 2017

Journal of antivirals & antiretrovirals, 2017, Vol.9 (1)

Hentig, Nils von

2017

Volltextzugriff (PDF)

Potential Drug Interactions Between cART and New Psychoactive Substances

Journal of antivirals & antiretrovirals, 2016, Vol.8 (2)

Hentig, Nils von

2016

Volltextzugriff (PDF)

Effects of the Oral, Direct Factor Xa Inhibitor Rivaroxaban on Platelet-Induced Thrombin Generation and Prothrombinase Activity

Journal of clinical pharmacology, 2007-11, Vol.47 (11), p.1398-1407

2007

Volltextzugriff (PDF)

Immune Response after Two Doses of the Novel Split Virion, Adjuvanted Pandemic H1N1 Influenza A Vaccine in HIV-1—Infected Patients

Clinical infectious diseases, 2011-01, Vol.52 (1), p.122-127

2011

Volltextzugriff (PDF)

Safety of pharmacoenhancers for HIV therapy

Expert review of clinical pharmacology, 2012-09, Vol.5 (5), p.557-568

2012

Volltextzugriff (PDF)

Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients

AIDS (London), 2010-06, Vol.24 (9), p.F31-F35

2010

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(34)

Publikationsform

Artikel
(49)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(35)
Science & Technology
(35)
Humans
(34)
Male
(27)
Adult
(25)
Pharmacology & Pharmacy
(24)
Biological And Medical Sciences
(23)
Medical Sciences
(23)
Female
(22)
Infectious Diseases
(20)
Middle Aged
(20)
Hiv Infections - Drug Therapy
(19)
Human Immunodeficiency Virus
(19)
Pharmacology. Drug Treatments
(19)
Hiv
(14)
Human Viral Diseases
(14)
Viral Diseases
(14)
Viral Diseases Of The Lymphoid Tissue And The Blood. Aids
(14)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(12)
Hiv Protease Inhibitors - Therapeutic Use
(12)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(34)
EZB Electronic Journals Library
(26)
Journals@Ovid
(23)
Ingenta.com
(16)
IngentaConnect Journals
(11)
Publisher or Other Site
(9)
Oxford Journals
(7)
Oxford Journals 2020 Medicine
(7)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(6)
Springer journals
(6)
Wiley Online Library
(5)
Wiley Online Library
(5)
Taylor & Francis Journals
(3)
Thieme Connect
(2)
Sage Journals
(2)
JSTOR
(1)
Taylor & Francis
(1)

12 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Repositioning HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors for the treatment of SARS-CoV-2 infection and COVID-19

Sequential Population Pharmacokinetic Modeling of Lopinavir and Ritonavir in Healthy Volunteers and Assessment of Different Dosing Strategies

Cross-sectional Assessment of the Consequences of a GTP Cyclohydrolase 1 Haplotype for Specialized Tertiary Outpatient Pain Care

Cytochrome P450 3A Inhibition by Atazanavir and Ritonavir, but Not Demography or Drug Formulation, Influences Saquinavir Population Pharmacokinetics in Human Immunodeficiency Virus Type 1-Infected Adults

Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapy

Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution

Determination of lopinavir/ritonavir concentrations in four different oral solutions for the application of antiretroviral therapy in very young, HIV-1-infected children

Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers

Messung von Plasmakonzentrationen antiretroviraler Arzneimittel in der HIV-Therapie

Evaluation of Platelet Activation by HIV Protease Inhibitors – The HIV-PLA II Study

Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults

The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors

Significant effects of tipranavir on platelet aggregation and thromboxane B[sub]2 formation in vitro and in vivo

Platelet–leucocyte adhesion markers before and after the initiation of antiretroviral therapy with HIV protease inhibitors

Pharmacokinetics of Saquinavir, Atazanavir, and Ritonavir in a Twice-Daily Boosted Double-Protease Inhibitor Regimen

Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and Ecarin Clotting Time

Association of Saquinavir Plasma Concentrations with Side Effects but Not with Antiretroviral Outcome in Patients Infected with Protease Inhibitor-Susceptible Human Immunodeficiency Virus Type 1

Decrease of Atazanavir and Lopinavir Plasma Concentrations in a Boosted Double Human Immunodeficiency Virus Protease Inhibitor Salvage Regimen

New Antiretrovirals on the Block: Pharmacological news from Croi 2017

New Antiretrovirals on the Block: Pharmacological news from Croi 2017

Potential Drug Interactions Between cART and New Psychoactive Substances

Effects of the Oral, Direct Factor Xa Inhibitor Rivaroxaban on Platelet-Induced Thrombin Generation and Prothrombinase Activity

Immune Response after Two Doses of the Novel Split Virion, Adjuvanted Pandemic H1N1 Influenza A Vaccine in HIV-1—Infected Patients

Safety of pharmacoenhancers for HIV therapy

Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients

Suchergebnisse filtern